Abstract
Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, Differentiation / immunology*
-
B-Lymphocytes / immunology
-
Child
-
Child, Preschool
-
Drug Resistance
-
Female
-
Forecasting
-
Glycolipids / immunology*
-
Graft vs Host Disease / classification
-
Graft vs Host Disease / prevention & control
-
Graft vs Host Disease / therapy*
-
Humans
-
Immunocompromised Host
-
Immunoglobulin M / therapeutic use*
-
Infant
-
Killer Cells, Natural / immunology
-
Lymphocyte Activation / immunology
-
Male
-
Membrane Lipids / immunology*
-
Methylprednisolone / therapeutic use*
-
Remission Induction
-
T-Lymphocytes / immunology
-
Transplantation Immunology
Substances
-
Antibodies, Monoclonal
-
Antigens, Differentiation
-
Glycolipids
-
Immunoglobulin M
-
Membrane Lipids
-
Methylprednisolone